Novo Holdings' earnings nearly doubled in 2024, despite Novo Nordisk's stock slump

Novo Nordisk Loses Another Executive as 28-Year Veteran Departs

Novo Nordisk A/S executive Camilla Sylvest is leaving the Danish drugmaker after almost three decades, the company’s second high-profile departure in a month as it battles to maintain its share of the booming market for weight-loss treatments.

Novo Holdings’ earnings nearly doubled in 2024, despite Novo Nordisk’s stock slump

Novo Holdings, the controlling shareholder of Ozempic-maker Novo Nordisk (NVO+0.19%), nearly doubled its annual income and investment returns in 2024. The life sciences–focused holding company reported Wednesday that its total income and investment returns reached a record 60 billion Danish krone ($8.7 billion), a 92% jump from 31.2 billion krone ($4.5 billion) the previous year. “2024 was a successful year for Novo Holdings, not only in terms o…

Novo Holdings' earnings nearly doubled in 2024, despite Novo Nordisk's stock slump

Novo Holdings, the controlling shareholder of Ozempic-maker Novo Nordisk (NVO), nearly doubled its annual income and investment returns in 2024.Read more...

The Novo Nordisk Foundation's investment company, Novo Holdings, delivered a return p¨ 60 billion kroner last †r.

Novo Nordisk announces significant leadership reshuffle

Novo Nordisk has announced major leadership changes, with EVP Camilla Sylvest departing and Ludovic Helfgott taking on an expanded role.

Novo owner after record: This is how we invest this yearThe strategy is the same, but right now the world is turbulent, and that is why the Novo Nordisk Foundation is holding on to the money. This is what Kasim Kutay, CEO of Novo Hold, says